Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.49 |
| ▸ | CHRM2 known ✓ | P08172 | 19/20 | 0.49 |
| ▸ | CHRM1 known ✓ | P11229 | 19/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4533943 | 1.00 | CHRM3 (0.49) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4527856 | 0.86 | CHRM2 (0.51) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6400127 | 0.82 | CHRM2 (0.60) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6398785 | 0.81 | CHRM2 (0.68) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3210018 | 0.80 | CHRM2 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3220852 | 0.80 | CHRM2 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3226674 | 0.80 | CHRM2 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6404700 | 0.79 | CHRM2 (0.63) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6400169 | 0.79 | CHRM2 (0.63) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6404269 | 0.79 | CHRM2 (0.63) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |